Endocrine Abstracts

Metabolic syndrome and insulin resistance persist 5 years after remission of Cushing’s syndrome (CS). Adiponectin and visfatin are two adipokines highly expressed in adipose tissue. Adiponectin is reduced in obesity and insulin-resistant states; visfatin has been shown in some studies to be reduced in obesity. The aim was to evaluate visfatin and adiponectin levels, body composition, insulin resistance and prevalence of metabolic syndrome in a cohort of women with long-te...

Two adipokines highly expressed in fat mass, adiponectin with antiinflammatory and antiatherogenic properties, and visfatin with an insulin-mimetic effect, are potential contributors to bone metabolism. In acromegaly data on adiponectin are contradictory and there are no data on visfatin.Objectives: To evaluate adiponectin and visfatin in acromegaly, compared to control subjects and to analyze their relationship with body composition and bone mineral mar...

Quality of life is impaired in patients who have suffered Cushing’s syndrome (CS).Aim: Evaluate QoL with the new questionnaire CushingQoL in Spanish patients in a clinical practice setting and compare it with a generic QoL questionnaire, EuroQoL-5 Dimensions (5D) and its Visual Analogue Scale (VAS).Patients and methods: Forty-three patients with CS (38 pituitary-dependent, 28 cured) were approached during their regular endocri...

High dose and long-term glucocorticoid (GC) therapy reduce bone mass and negatively affect the metabolic profile. Patients in remission after successful treatment of Cushing’s syndrome (CS) often present hypoadrenalism and require long-term GC replacement.Objective: To evaluate the effect of GC therapy on bone and metabolic parameters in women after long-term remission of CS. Materials and methods: Thirty-two women (mean age: 50±14 years) with ...